Guest Editor(s)
-
- Guido Guenther Heinrich Gerken, MD
- Director emeritus of the Department of Gastroenterology and Hepatology, University of Essen, Essen, Germany.
Ethics committee of the European Association for the Study of the Liver (EASL)
Website | E-mail
Special Issue Introduction
Hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the second most common cause of cancer-related death worldwide. However, HCC is a major global health problem with geographic, ethnic and racial variation worldwide. In general HCC develops on the basis of a chronic liver disease, mostly associated to liver cirrhosis as the most important pathogenetic risk factor. There are several viral, non viral, metabolic, environmental and genetic factors, etc. as risk factors for the development of HCC, but currently NAFLD/NASH are significantly increasing as leading HCC triggering factor worldwide.
For our special issue, we focus on hepatoma risk factors, and topics should be discussed such as the importance of HCV, HBV, NAFLD/NASH/metabolic syndrome, hereditary disease including Hemochromatosis/Wilson’s disease, Alcoholic Steatohepatitis, autoimmune diseases including autoimmune hepatitis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, aflatoxin/nicotine exposure, in addition to prevention strategies (vaccination, nutrition, treatment) and the value of biomarkers (AFP) in the early diagnostic and prediction in patients at risk for HCC.
Submission Deadline
31 May 2020
Hepatoma Research
hrjournal.net
